Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations.

dc.contributor.authorBlanco Ares, Gonzalo, 1989-ca
dc.contributor.authorPuiggros Metje, Anna Mariaca
dc.contributor.authorRodríguez-Rivera, Maríaca
dc.contributor.authorGimeno Vázquez, Evaca
dc.contributor.authorAbella Monreal, Eugeniaca
dc.contributor.authorFerrer Del Alamo, Anaca
dc.contributor.authorEspinet Solà, Blancaca
dc.date.accessioned2017-02-08T12:41:57Z
dc.date.available2017-02-08T12:41:57Z
dc.date.issued2016
dc.description.abstractPatients with chronic lymphocytic leukemia (CLL) harboring TP53 aberrations (TP53abs; chromosome 17p deletion and/or TP53 mutation) exhibit an unfavorable clinical outcome. Chromosome 8 abnormalities, namely losses of 8p (8p-) and gains of 8q (8q+) have been suggested to aggravate the outcome of patients with TP53abs. However, the reported series were small, thus hindering definitive conclusions. To gain insight into this issue, we assessed a series of 101 CLL patients harboring TP53 disruption. The frequency of 8p- and 8q+ was 14.7% and 17.8% respectively. Both were associated with a significantly (P < 0.05) higher incidence of a complex karyotype (CK, ≥3 abnormalities) detected by chromosome banding analysis (CBA) compared to cases with normal 8p (N-8p) and 8q (N-8q), respectively. In univariate analysis for 10-year overall survival (OS), 8p- (P = 0.002), 8q+ (P = 0.012) and CK (P = 0.009) were associated with shorter OS. However, in multivariate analysis only CK (HR = 2.47, P = 0.027) maintained independent significance, being associated with a dismal outcome regardless of chromosome 8 abnormalities. In conclusion, our results highlight the association of chromosome 8 abnormalities with CK amongst CLL patients with TP53abs, while also revealing that CK can further aggravate the prognosis of this aggressive subgroup.ca
dc.description.sponsorshipThis work has been supported by the following grants: PI11/01621, PI15/00437, RD09/0076/00036,RD12/0036/0044, RD12/0036/0069 and PT13/0010/0005 FEDER, Instituto de Salud Carlos III, Spanish Ministry of Economy and Competitiveness; 2014/SGR585 from Generalitat de Catalunya; “Xarxa de Bancs de tumors” sponsored by Pla Director d’Oncologia de Catalunya (XBTC) and Fundació La Caixa; the Swedish Cancer Society, the Swedish Research Council, the Lion’s Cancer Research Foundation, and Selander’s Foundation, Uppsala; H2020 “AEGLE, An analytics framework for/nintegrated and personalized healthcare services in Europe” by the EU.
dc.format.mimetypeapplication/pdfca
dc.identifier.citationBlanco G, Puiggros A, Baliakas P, Athanasiadou A, García-Malo M, Collado R. et al. Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations. Oncotarget. 2016 Dec 6;7(49):80916-80924. doi: 10.18632/oncotarget.13106ca
dc.identifier.doihttp://dx.doi.org/10.18632/oncotarget.13106
dc.identifier.issn1949-2553
dc.identifier.urihttp://hdl.handle.net/10230/28084
dc.language.isoengca
dc.publisherImpact Journalsca
dc.relation.ispartofOncotarget. 2016 Dec 6;7(49):80916-24
dc.rightsAll site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.ca
dc.rights.accessRightsinfo:eu-repo/semantics/openAccessca
dc.rights.urihttps://creativecommons.org/licenses/by/3.0/ca
dc.subject.otherLeucèmia aguda -- Aspectes genèticsca
dc.subject.otherLeucèmia limfocíticaca
dc.titleKaryotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations.ca
dc.typeinfo:eu-repo/semantics/articleca
dc.type.versioninfo:eu-repo/semantics/publishedVersionca

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
blanco-onc-kari.pdf
Size:
777.38 KB
Format:
Adobe Portable Document Format

License

Rights